Navigation Links
Pfizer unveils anti-smoking drug

Pfizer's new drug was inspired by a natural remedy tested by doctors in the Soviet Union in the late 1960s. The Soviet doctors had tested a chemical called cytisine, derived from a weed sometimes called false tobacco, as a pill to help smokers kick the habit. They reported that cytisine partially activated the nicotine receptors in the brain without being addictive.
Pfizer Inc. unveiled an experimental drug to help people quit smoking //that could become the drugmaker's next blockbuster.

In clinical trials involving several hundred smokers, the New York-based company said almost half of smokers given this oral medicine, called Varenicline, were able to quit smoking after only seven weeks.

In the same trial, only 16 percent of people receiving sugar pills managed to stop, while 33 percent of patients who received Zyban, a pill sold as Wellbutrin for depression, were able to quit.

"This is a significant improvement over results achieved with Zyban, an antidepressant approved as an aid to smoking cessation." Side effects of the Pfizer drug appeared negligible so far, and the drug has "an excellent safety profile," said Pfizer's spokeswoman.

Varenicline is currently in the final phase of widespread human clinical trials, but there's no timeline for when the anti-smoking drug might hit the market.

The company, however, cautioned that the results of its big clinical studies will take time, and a positive outcome isn't always guaranteed. Pfizer said it is unclear how long patients need to be on Varenicline after quitting.

Page: 1

Related medicine news :

1. The Effectiveness Of The Breast Cancer Drug By Pfizer
2. New Drug Exubera (Oral Inhaled Insulin) To Be Monitored By Pfizer
3. Erectile Dysfunction Drug Viagra Launched In India By Pfizer
4. Pfizer’s Eraxis Approved By The FD
5. Pfizer Launches Viagra For Lung Disease In UK
6. Pfizer Acquires Worldwide Rights For New Overactive Bladder Drug
7. Pfizer Commences Its Advertising for Celebrex with All the Warnings
8. FDA Approves Pfizer’s Anti-smoking Dru
9. Pfizer vouches safety of long-term inhaled insulin.
10. NICE Setback Rules for Pfizers Inhaled Insulin
11. Patency On Two Drugs From Merck & Pfizer’s To Expire Soo
Post Your Comments:

(Date:11/25/2015)... ... November 25, 2015 , ... Additional breast cancers found ... mammography, according to a study published online in the journal Radiology. Researchers said ... may necessitate a change in treatment. , Breast MRI is the most sensitive ...
(Date:11/25/2015)... ... November 25, 2015 , ... Medical Solutions, one of ... its stellar workplace culture with the company’s Cincinnati office being named a finalist ... office was named a finalist in Cincinnati Business Courier’s 13th annual Greater Cincinnati ...
(Date:11/25/2015)... ... , ... On November 10, 2015, Bohrer Brady, LLC filed a class and ... a home health care worker who provided companionship services for the elderly, ill or ... by Humana, Inc., Humana at Home, Inc., and SeniorBridge Family Companies (CT), Inc. since ...
(Date:11/25/2015)... ... , ... Dental professionals who would like to become more proficient on their ... Mark Iacobelli’s Advanced Implant Mentoring (AIM) CE course. Courses will be held on December ... of Advanced Implant Mentoring (AIM), Dr. Iacobelli and Dr. D’Orazio are proud to announce ...
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... On November ... of Tri Lite’s personal heating products business. Cozy Products explains what this ... heaters that fit in well with the Cozy Products business model: to sell personal ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... AVIV, Israel , November 25, 2015 ... (NASDAQ: KTOV ) (TASE: KTOV), a biopharmaceutical company ... simultaneous treatment of various clinical conditions, today announced the ... 3,158,900 American Depository Shares ( ADSs ), each representing ... purchase up to 3,158,900 ADSs. The ADSs and warrants ...
(Date:11/25/2015)... Nov. 25, 2015 Allergan plc (NYSE: ... and Rugen Therapeutics, a start-up  biotechnology company focused ... CNS disorders and funded by the F-Prime Biomedical ... entered into an exclusive collaboration to support the ... Spectrum Disorders (ASD) and Obsessive Compulsive disorders (OCD). ...
(Date:11/25/2015)... TEL AVIV, Israel , November 25, 2015 /PRNewswire/ ... firms (the "New Investors"), pursuant to which BioLight and ... in BioLight,s IOPtima Ltd. subsidiary ("IOPtima") via a private ... global commercialization of its innovative IOPtimate™ system used in ... a regulatory approval pathway process for the IOPtimate™ system ...
Breaking Medicine Technology: